Searchable abstracts of presentations at key conferences in endocrinology

ea0056cet1 | Clinical Endocrinology Trust Lecture | ECE2018

Growth Hormone: not too much… not too less..!

Chanson Philippe

Growth hormone (GH) and insulin-like growth factor-I (IGF-I) have important metabolic actions. GH/IGF-I excess and GH deficiency are each associated with ‘opposing’ comorbidities that often mirror one another. Cardiac and vascular comorbidity demonstrates that ‘too much’ may be as bad as ‘too little’. An association between acromegaly and increased cardiac mortality has long been claimed. This was based on epidemiological studies of patients treat...

ea0041ep1057 | Thyroid (non-cancer) | ECE2016

Antithyroid arthritis syndrome

Paepegaey Anne-Cecile , Mavromati Maria , Chanson Philippe , Salenave Sylvie

The most frequent side effects of antithyroid drugs are skin reactions (6%), gastrointestinal effects (5%) and arthralgia (5%). Other complications such as antithyroid arthritis syndrome (1%), agranulocytosis (0.5%) and hepatitis (0.2%) occur rarely.We describe the case of a 20-year-old woman with Graves’ disease. Two weeks after the beginning of carbimazole therapy, she developed an urticarial reaction that led to discontinuation of treatment. Neve...

ea0081rc4.8 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Impaired insulin secretion without changes in insulin sensitivity explains hyperglycemia in patients with acromegaly treated by pasireotide LAR

Wolf Peter , Dormoy Alexandre , Maione Luigi , Salenave Sylvie , Young Jacques , Kamenicky Peter , Chanson Philippe

Background: Pasireotide is a second line treatment for acromegaly. Besides the growth hormone (GH) lowering efficacy, clinical use is limited by side effects on glycemic control. The aim of this study was to evaluate longitudinal changes in beta-cell function and insulin sensitivity induced by pasireotide therapy in patients with acromegaly.Methods: We performed a retrospective study in 33 patients. Efficacy (GH and IGF-I concentrations; tumor size) and ...

ea0063p253 | Pituitary and Neuroendocrinology 1 | ECE2019

What patients with acromegaly have to say about their diagnostic pathway: A qualitative study

Sibeoni Jordan , Manolios Emilie , Verneuil Laurence , Chanson Philippe , Revah-Levy Anne

Background: Acromegaly is a rare disease with a long and complex diagnostic pathway leading to a substantial diagnostic delay associated with an increased risk of comorbidities and psychosocial deterioration. Qualitative methods are the gold standard to explore patients’ perspectives, focusing on how individuals understand and report what they are experiencing. To the best of our knowledge, no qualitative study has yet examined the diagnostic pathway of subjects with acro...

ea0063p731 | Pituitary and Neuroendocrinology 2 | ECE2019

Therapeutic decisions in acromegaly according to disease control in patients with acromegaly with or without prior treatment: data from baseline analysis of the SAGIT® validation study

Giustina Andrea , Bronstein Marcello , Chanson Philippe , Petersenn Stephan , Casanueva Felipe , Sert Caroline , Houchard Aude , Melmed Shlomo

Background: The SAGIT® instrument, designed to assist clinicians in staging and managing acromegaly, is undergoing validation. A descriptive analysis of SAGIT Validation study baseline data revealed discrepancies between investigator-evaluated disease-control status, disease activity, hormonal control, and treatment decisions in acromegaly.Objective: To describe the baseline characteristics of patients in the SAGIT® valida...

ea0063p821 | Adrenal and Neuroendocrine Tumours 3 | ECE2019

The malignant potential of oncocytic adrenal tumours should not be underestimated

Fontaine Benedicte , Flaus-Furmaniuk Anna , Jelloul Emna , Mosbach Helena , Maione Luigi , Chanson Philippe , Debussche Xavier

Background: Oncocytic neoplasms are rare adrenal tumours usually considered as benign and non-functional. Conversely, in recent large nationwide study from COMETE network over 50% of the oncocytic adrenocortical tumours were diagnosed as carcinoma according to Lin Weiss-Bisceglia-score. However, until now only 11 cases of metastatic oncocytoma were reported in English literature.Case report: A 54-year-old man with history of abdominal pain and weight los...

ea0049gp189 | Pituitary & endocrine Tumours | ECE2017

Evaluation of pituitary toxicity after radiotherapy for cerebral chondrosarcomas in adult patients

Laroche Suzanne , Feuvret Loic , Beauchet Alain , Dendale Remi , Chanson Philippe , Bruckert Eric , Jublanc Christel

Pituitary dysfunction can be a consequence of cranial radiotherapy. It usually occurs years after the treatment. However little is known on risk factors for pituitary dysfunction. The object of this study was to evaluate radiation induced pituitary toxicity of proton beam therapy in a cohort of adult chondrosarcoma patients.The files of 113 patients were reviewed. Mean age at the beginning of radiotherapy was 43 years old (18–76). Mean dose delivere...

ea0041gp163 | Pituitary - Clinical (1) | ECE2016

Medical treatment of macroprolactinomas Escalation and de-escalation of dopamine agonist dose

Paepegaey Anne-Cecile , Salenave Sylvie , Kamenicky Peter , Young Jacques , Chanson Philippe

Background: Cabergoline (CAB) is the most effective dopamine agonist (DA) used for the treatment of macroprolactinoma. Few data on the dose of CAB necessary for achieving and maintaining normal prolactin (PRL) levels are available. We aimed to study these parameters in a large series of patients with macroprolactinomasMethods: We retrospectively analysed the clinical, biochemical and imaging features at diagnosis and the treatment response to CAB (dose n...

ea0032oc5.6 | Reproduction | ECE2013

INSL3 in 268 male patients with congenital hypogonadotropic hypogonadism (CHH): effects of different modalities of hormonal treatment

Trabado Severine , Maione Luigi , Sarfati Julie , Salenave Sylvie , Chanson Philippe , Brailly-Tabard Sylvie , Young Jacques

Context: Insulin-like peptide three (INSL3) is a testicular hormone, secreted by Leydig cells, during fetal life, in newborns, and after puberty. These 3 phases of testicular activation are impaired in CHH.Objective: To evaluate in a single center circulating INSL3 in a significant series of men with CHH in order to asses the consequences of pre- and postnatal gonadotropin deficiency, to specify the INSL3 regulation by gonadotropins and to evaluate the p...

ea0029p1080 | Neuroendocrinology | ICEECE2012

CT Scan of the anterior skull base in Kallmann syndrome reveals specific ethmoid abnormalities

Maione L. , Benadjaoud S. , Ducreux D. , Sinisi A. , Chanson P. , Benoudiba F. , Young J.

Context: Kallmann syndrome (KS) is a developmental disease associating congenital hypogonadotropic hypogonadism (CHH) and sense of smell impairment owing to olfactory structures (OS) aplasia/hypoplasia. Although rhinencephalic MRI allows to detect specific KS OS abnormalities useful to discriminate KS from normosmic CHH (nCHH), this technique is not efficient enough to study anterior skull bone structures.Objectives: To search for specific anterior skull...